Figure 2.

ABT-737 + vesicular stomatitis virus (VSV) therapy selectively reduces viability of chronic lymphocytic leukemia (CLL) cells ex vivo and in vivo. MTT assay showing sensitivity of CD19⁺ CD5⁺ cells of (a) untreated (n = 3) and (b) non-responder (n = 3) CLL patients to VSV + ABT-737 combination treatment in comparison to CD19⁺ CD5⁻ cells (mean ± SD). White bars indicate control cells; light gray bars indicate ABT-737 treatment; dark gray bars indicate VSV infection, and black bars indicate VSV + ABT-737 treatment. (c) Tumor volumes were calculated as ½ (length × width)² and values are expressed as the mean ± SD of tumor volume (n = 7). (d) Animals were evaluated for signs of stress such as infection, dehydration, weight loss, and limb paralysis. Mice were killed when tumor volumes exceed 2,000 mm³. *P ≤ 0.05 comparing tumor size between the single and combination treatment groups. MTT, 3-(4,5-dimethylthiazol)-2,5-diphenyl tetrazolium; NT, non-treated.